Description: MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Home Page: www.MAIABiotech.com
MAIA Technical Analysis
444 West Lake Street
Chicago,
IL
60606
United States
Phone:
312 416 8592
Officers
| Name | Title |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, Pres, CEO & Chairman of Directors |
| Mr. Joseph F. McGuire | Chief Financial Officer |
| Dr. Mihail Obrocea M.D. | Chief Medical Officer & Head of Devel. |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Sec. |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9571 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-07-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |